secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001159036-26-000035
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme appoints David Ramsay as Interim CFO effective March 23, 2026
----------------------------------------------------------------------

- Monthly salary of $50,000; initial grant of 10,000 RSUs vesting June 30, 2026, plus 2,500 more if still interim after July 1.
- Ramsay previously served as Halozyme CFO from 2003-2009 and 2013-2015, and guided company from private to public.
- Company is actively searching for a permanent CFO via a leading executive search firm.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903626000035/0001159036-26-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903626000035/halo-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001159036-26-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer